Market Place
Sourcing Support
All News #Library
Sciences
Webinar Highlights NGAL Biomarker in New Kidney Care Frontiers
11 Sep 2025 //
GLOBENEWSWIRE
ProNephro AKI (NGAL) commercialization for US diagnostics
27 Jun 2025 //
GLOBENEWSWIRE
BioPorto Enters Market Maker Deal With Danske, Names IR Head
27 Feb 2025 //
GLOBENEWSWIRE
BioPorto A/S appoints new interim Chairman of the Board
29 Jan 2025 //
GLOBENEWSWIRE
BioPorto Showcases ProNephro AKI & NGAL Test at Conferences
08 Nov 2024 //
GLOBENEWSWIRE
BioPorto Partners with Beckman Coulter for AKI NGAL Tests
28 Oct 2024 //
#N/A
BioPorto Serves Nine Of The Top Ten US Children’s Hospitals
22 Oct 2024 //
GLOBENEWSWIRE
BioPorto Names PI And CRO For USA ICU Adult AKI Clinical Study
10 Oct 2024 //
GLOBENEWSWIRE
NGAL Biomarker Shows Potential Beyond Early AKI Diagnosis
17 Jul 2024 //
GLOBENEWSWIRE
Roche Diagnostics and BioPorto expand collaboration
20 Feb 2024 //
GLOBENEWSWIRE
FDA Clears First Test to Identify Hospitalized Children at Risk for AKI
08 Dec 2023 //
GLOBENEWSWIRE
US healthcare executive Dr. Ninfa Saunders to be nominated at general meeting
29 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.